Comparing Senti Biosciences (SNTI) & Its Peers

Senti Biosciences (NASDAQ:SNTI – Get Rating) is one of 283 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Senti Biosciences to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Senti Biosciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0	2	2	0	2.50
Senti Biosciences Competitors	1065	4141	11197	176	2.63

Senti Biosciences presently has a consensus target price of $4.50, indicating a potential upside of 358.76%. As a group, “Biological products, except diagnostic” companies have a potential upside of 67.53%. Given Senti Biosciences’ higher probable upside, equities research analysts plainly believe Senti Biosciences is more favorable than its rivals.

Risk & Volatility

Senti Biosciences has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Senti Biosciences’ rivals have a beta of 1.05, meaning that their average stock price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

40.8% of Senti Biosciences shares are owned by institutional investors. Comparatively, 46.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 8.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 15.5% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Senti Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	-1,457.24%	-48.76%	-35.49%
Senti Biosciences Competitors	-4,068.84%	-137.64%	-41.92%

Earnings and Valuation

This table compares Senti Biosciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Senti Biosciences	$4.29 million	-$58.21 million	-0.47
Senti Biosciences Competitors	$705.49 million	$87.48 million	-2.50

Senti Biosciences’ rivals have higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Senti Biosciences rivals beat Senti Biosciences on 7 of the 13 factors compared.

Senti Biosciences Company Profile

(Get Rating)

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells, while sparing healthy cells in the body. The company was incorporated in 2016 and is headquartered in South San Francisco, California.